1. Home
  2. QDEL vs PHVS Comparison

QDEL vs PHVS Comparison

Compare QDEL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$29.38

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$26.03

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QDEL
PHVS
Founded
1979
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
QDEL
PHVS
Price
$29.38
$26.03
Analyst Decision
Hold
Buy
Analyst Count
6
9
Target Price
$39.33
$39.44
AVG Volume (30 Days)
857.8K
475.7K
Earning Date
02-11-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,714,400,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.50
$11.51
52 Week High
$49.45
$29.80

Technical Indicators

Market Signals
Indicator
QDEL
PHVS
Relative Strength Index (RSI) 58.54 53.90
Support Level $28.39 $25.27
Resistance Level $29.62 $26.09
Average True Range (ATR) 1.16 1.20
MACD -0.03 0.04
Stochastic Oscillator 67.00 66.98

Price Performance

Historical Comparison
QDEL
PHVS

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: